German Industry Is Winning Medtech Aids Quality Battle, If Slowly
Executive Summary
The price versus quality standoff surrounding the supply of medtech aids and assistive-care products prescribed in the German primary- and ambulatory-care settings goes on. A ban on tenders, which can imbalance the market with large supplies of lower-quality imports, has soothed industry’s frustrations, but the battle is not over yet.
You may also be interested in...
New Health Law Should Mean Faster Access To Diagnostics Innovation, Germany’s IVD Industry Says
Germany’s new draft health-care access law includes provisions to make the currently complicated, under-used and slow innovation "fast-tracking" tools more practical. Manufacturers of products that can address unmet needs should welcome the new TSVG law, currently in draft, says the national IVDs industry association. But it’s not all good news for industry.
Medtech Under Pressure? German Industry Urges Realistic Patient Safety And Innovation Balance
Meaningful medtech advances that have the potential to revolutionize patient care cannot happen by eliminating risk entirely, but it’s a balance that European stakeholders are failing to achieve consistently. This is so in Germany too, says the BVMed industry association, with negative consequences for those at the sharp end of innovation – the SMEs and start-ups who originate a vast proportion of medtech advances.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.